<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02033551</url>
  </required_header>
  <id_info>
    <org_study_id>M14-144</org_study_id>
    <secondary_id>2013-003137-16</secondary_id>
    <nct_id>NCT02033551</nct_id>
  </id_info>
  <brief_title>A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors</brief_title>
  <official_title>An Extension Study to Evaluate the Safety of Veliparib as Single Agent Therapy or in Combination With Chemotherapy in Subjects With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an extension study to evaluate the safety of Veliparib monotherapy or in combination&#xD;
      with Carboplatin plus Paclitaxel or modified Folinic Acid/Fluorouracil/Irinotecan (FOLFIRI)&#xD;
      in subjects with solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>Measured up to 30 days after the last dose of study drug.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Radiographic evaluation at Screening and every 6-9 weeks until the final visit, up to 18 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Every 3 months after the subject is registered off study up to 2 years post discontinuation or until date of death from any cause, whichever comes first.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Disease Progression (TTP)</measure>
    <time_frame>Assessed at each visit up to 18 months after the last subject has enrolled in the study.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Radiographic evaluation starting from the first day of study drug until documented progression or date of death, whichever comes first, until the subject is registered off study.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory Tests</measure>
    <time_frame>Up to 18 months.</time_frame>
    <description>Hematology, Chemistry, Urinalysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram</measure>
    <time_frame>Up to 18 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Assessment</measure>
    <time_frame>Up to 18 months.</time_frame>
    <description>A computerized tomography scan to document the size of the tumor.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Colon Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Arm A - Veliparib Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will be dosed with Veliparib continuous dosing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B - Veliparib in Combination with Carboplatin &amp; Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects enrolled will receive Veliparib in combination with Carboplatin and Paclitaxel and have an option to move to Veliparib monotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C Veliparib in Combination with Modified FOLFIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be given Veliparib in combination with modified FOLFIRI. The subject will have the opportunity to receive Veliparib as monotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Veliparib</intervention_name>
    <arm_group_label>Arm A - Veliparib Monotherapy</arm_group_label>
    <arm_group_label>Arm B - Veliparib in Combination with Carboplatin &amp; Paclitaxel</arm_group_label>
    <arm_group_label>Arm C Veliparib in Combination with Modified FOLFIRI</arm_group_label>
    <other_name>ABT-888</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <arm_group_label>Arm B - Veliparib in Combination with Carboplatin &amp; Paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>Arm B - Veliparib in Combination with Carboplatin &amp; Paclitaxel</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI</intervention_name>
    <description>combination of Fluorouracil, leucovorin and irinotecan</description>
    <arm_group_label>Arm C Veliparib in Combination with Modified FOLFIRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must have confirmed solid malignancy that is metastatic, and standard curative&#xD;
             measures or other therapy that may provide clinical benefit do not exist or are no&#xD;
             longer effective.&#xD;
&#xD;
          -  For Veliparib monotherapy (must have tumor with defects in DNA repair mechanisms (BRCA&#xD;
             mutation or high grade ovarian cancer or solid tumors for combination therapy.&#xD;
&#xD;
          -  If the subject has known brain metastases must have clinically controlled neurologic&#xD;
             symptoms, defined as surgical excision and/or radiation therapy followed by 21 days of&#xD;
             stable neurologic function and no evidence of Central Nervous System (CNS) disease&#xD;
             progression as determined by comparing a computed tomography (CT) scan or magnetic&#xD;
             resonance imaging (MRI) scan performed during screening to a prior scan performed at&#xD;
             least 4 weeks earlier and provided that the subject is asymptomatic, has no evidence&#xD;
             of cavitation or hemorrhage, and does not require corticosteroids (must have&#xD;
             discontinued steroids at least 3 months prior to study drug administration).&#xD;
&#xD;
          -  Subject must have adequate bone marrow, renal and hepatic function per local&#xD;
             laboratory reference range.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has a clinically significant and uncontrolled major medical condition(s)&#xD;
             including but not limited to:&#xD;
&#xD;
          -  Uncontrolled seizure disorder, including focal or generalized seizure within the last&#xD;
             12 months;&#xD;
&#xD;
          -  Uncontrolled nausea/vomiting/diarrhea;&#xD;
&#xD;
          -  Active uncontrolled infection;&#xD;
&#xD;
          -  Symptomatic congestive heart failure;&#xD;
&#xD;
          -  Unstable angina pectoris or cardiac arrhythmia;&#xD;
&#xD;
          -  Psychiatric illness/social situation that would limit compliance with study&#xD;
             requirements;&#xD;
&#xD;
          -  Any medical condition, which in the opinion of the study investigator, places the&#xD;
             subject at an unacceptably high risk for toxicities.&#xD;
&#xD;
          -  Subjects who have hypersensitivity to Carboplatin, Paclitaxel or Cremophor should be&#xD;
             excluded from arm B.&#xD;
&#xD;
          -  Subject has received any of the following anti-cancer therapies 21 days prior to the&#xD;
             first dose of study drug or a biologic agent for anti-neoplastic intent within 30 days&#xD;
             prior to the first dose of study drug.&#xD;
&#xD;
          -  Subject who requires parenteral nutrition, tube feeding or has evidence of a partial&#xD;
             bowel obstruction or perforation within 28 days prior to study drug.&#xD;
&#xD;
          -  The subject has had another active malignancy within the past 3 years except for any&#xD;
             cancer in situ that the Principal Investigator considers to be cured.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stacie Shepherd, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 117416</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 117415</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 117337</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 117338</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 117451</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>January 8, 2014</study_first_submitted>
  <study_first_submitted_qc>January 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2014</study_first_posted>
  <last_update_submitted>September 26, 2016</last_update_submitted>
  <last_update_submitted_qc>September 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastric Cancer</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>PARP Inhibitor</keyword>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Solid Tumors</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Colon Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Veliparib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

